Article
A preclinical model of minimal residual cancer in the muscle highlights challenges associated with adenovirus-mediated p53 gene transfer.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jun 2002
Oakley Roth, Phillips Elaine, Hooper Richard, Wilson Deborah, Partridge Max
Abstract excerpt
PURPOSE: Clinical studies have revealed that tumors may recur at the operative site if radioresistant p53 mutation-positive residual disease remains in the body after treatment. Destruction of these remaining malignant cells, which can be present in both mucosal and deep muscle margins, may be achieved using p53-mediated gene transfer techniques. Most preclinical studies designed to assess the feasibility of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
